Scailyte quarterly update
Scailyte quarterly update June, highlighting the discovery of a new biomarker for diagnosing endometriosis. Prof Michael Brenner (Harvard Medical School) joined as a scientific advisor to support the Board and management in defining our clinical and R&D strategy. Here is his statement about our company – “With their approach to leverage single-cell data and artificial intelligence for biomarker discovery, Scailyte is spot on, doing something that has huge potential and at the right time.” Read more below:
Read our previous quarterly update here.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology
Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...
Recent News
Pitch-nic Expo
We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...
Recent News
Targets & Cell Types in Immuno-Oncology Europe 2023
Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Recent News
NextGen Omics 2023
Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...
Recent News
Recent News
ScaiDigest Volume 5: Unlocking the Secrets of AML
Read Diana's insightful post and stay at the forefront of scientific advancements in the field!
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
ScaiDigest Volume 6: Variational autoencoders (VAEs) in biology
Welcome to the 6th edition of ScaiDigest, where we explore cutting-edge research in single-cell anal...
Recent News
Pitch-nic Expo
We're excited to share that our Senior Vice President of Corporate & Technology Development, Corinne...
Targets & Cell Types in Immuno-Oncology Europe 2023
Scailyte is part of Targets & Cell Types in Immuno-Oncology Europe 2023 event on November 14-15 in B...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
NextGen Omics 2023
Scailyte is gearing up for NextGen Omics 2023, one of the most scientifically engaging events in Lon...
Recent News
SITC 2023
Diana Stoycheva and Julian Spagnuolo will be sharing Scailyte’s science at a poster #201, and will...
ScaiDigest Volume 5: Unlocking the Secrets of AML
Read Diana's insightful post and stay at the forefront of scientific advancements in the field!